Odronextamab + REGN5837
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Non-Hodgkins Lymphoma (B-NHL)
Conditions
B-cell Non-Hodgkins Lymphoma (B-NHL)
Trial Timeline
Apr 12, 2023 → May 16, 2029
NCT ID
NCT05685173About Odronextamab + REGN5837
Odronextamab + REGN5837 is a phase 1 stage product being developed by Regeneron Pharmaceuticals for B-cell Non-Hodgkins Lymphoma (B-NHL). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05685173. Target conditions include B-cell Non-Hodgkins Lymphoma (B-NHL).
What happened to similar drugs?
3 of 20 similar drugs in B-cell Non-Hodgkins Lymphoma (B-NHL) were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05685173 | Phase 1 | Recruiting |
Competing Products
20 competing products in B-cell Non-Hodgkins Lymphoma (B-NHL)